Ligand Pharma (LGND)

83.44 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/8/21 *Est.)

Latest Headlines

Form 8-K LIGAND PHARMACEUTICALS For: Dec 02 December 3, 2020 8:13 AM - SEC Filing Form 8-K LIGAND PHARMACEUTICALS For: Nov 23 November 23, 2020 8:33 AM - SEC Filing Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies November 23, 2020 8:30 AM - BizWire Form DEF 14A LIGAND PHARMACEUTICALS For: Dec 15 November 12, 2020 4:16 PM - SEC Filing Form 4 LIGAND PHARMACEUTICALS For: Nov 09 Filed by: HIGGINS JOHN L November 10, 2020 7:41 PM - SEC Filing Form 10-Q LIGAND PHARMACEUTICALS For: Sep 30 November 6, 2020 4:13 PM - SEC Filing Ligand Pharma's (LGND) Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT for Treatment of Status Epilepticus in Adult and Pediatric Patients November 6, 2020 2:17 PM - StreetInsider Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients November 6, 2020 2:16 PM - BizWire Form 4 LIGAND PHARMACEUTICALS For: Nov 02 Filed by: Patel Sunil November 4, 2020 4:19 PM - SEC Filing Form PRE 14A LIGAND PHARMACEUTICALS For: Dec 15 October 30, 2020 5:03 PM - SEC Filing Form 8-K LIGAND PHARMACEUTICALS For: Oct 26 October 30, 2020 4:08 PM - SEC Filing Ligand Pharma (LGND) Tops Q3 EPS by 6c, Offers FY20 and FY21 Guidance October 30, 2020 8:07 AM - StreetInsider Form 8-K LIGAND PHARMACEUTICALS For: Oct 30 October 30, 2020 8:04 AM - SEC Filing Ligand Reports Third Quarter 2020 Financial Results October 30, 2020 8:00 AM - BizWire CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) October 26, 2020 7:23 PM - PR NewsWire Ligand Pharma (LGND) Says its Captisol Technology Plays Key Role in Manufacture of Gilead's COVID-19 Treatment Veklury October 23, 2020 8:34 AM - StreetInsider Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment October 23, 2020 8:30 AM - BizWire Ligand Pharma (LGND) PT Lowered to $195 at Craig-Hallum October 21, 2020 9:02 AM - StreetInsider Ligand Pharma (LGND) Provides Highlights from Today’s Investor Day Event October 20, 2020 2:10 PM - StreetInsider Ligand Provides Highlights from Today’s Investor Day Event October 20, 2020 2:05 PM - BizWire Form 8-K LIGAND PHARMACEUTICALS For: Oct 20 October 20, 2020 10:54 AM - SEC Filing Ligand’s Third Quarter Financial Results to be Reported October 30th October 19, 2020 4:02 PM - BizWire Form 8-K LIGAND PHARMACEUTICALS For: Oct 11 October 13, 2020 8:44 AM - SEC Filing Ligand Pharma (LGND) to Divest Vernalis Research Operations October 12, 2020 9:00 AM - StreetInsider Ligand to Divest Vernalis Research Operations October 12, 2020 9:00 AM - BizWire Ligand Pharma (LGND), HITGEN Report Agreement to Acquire Vernalis ltd. October 12, 2020 6:32 AM - StreetInsider HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery October 12, 2020 6:24 AM - BizWire Form SC 13G/A LIGAND PHARMACEUTICALS Filed by: WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC October 8, 2020 9:18 AM - SEC Filing Barclays Starts Ligand Pharma (LGND) at Overweight October 6, 2020 4:40 AM - StreetInsider Ligand to Host Virtual Investor Day on October 20th October 2, 2020 8:00 AM - BizWire Form 8-K LIGAND PHARMACEUTICALS For: Oct 01 October 1, 2020 8:42 AM - SEC Filing Ligand (LGND) Completes Acquisition of Pfenex Inc. (PFNX) October 1, 2020 8:26 AM - StreetInsider Ligand Completes Acquisition of Pfenex Inc. October 1, 2020 8:24 AM - BizWire Ligand Pharma (LGND) Announces Expiration of Tender Offer for Shares of Pfenex (PFNX), Expects Merger to Close on October 1 September 30, 2020 8:04 AM - StreetInsider Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc. September 30, 2020 8:00 AM - BizWire CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China September 29, 2020 11:22 PM - BizWire Form 8-K LIGAND PHARMACEUTICALS For: Sep 21 September 23, 2020 8:07 AM - SEC Filing Ligand Pharma (LGND) Says Captisol Business is Positioned for Major Growth, Forecasts 2021 Captisol Material Sales of $200 Million September 23, 2020 8:04 AM - StreetInsider Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million September 23, 2020 8:00 AM - BizWire Form 8-K LIGAND PHARMACEUTICALS For: Sep 08 September 10, 2020 4:44 PM - SEC Filing Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences September 10, 2020 8:00 AM - BizWire Full Article List